Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.55 |
| ▸ | JAK1 | P23458 | 5/20 | 0.48 |
| ▸ | JAK2 | O60674 | 4/20 | 0.48 |
| ▸ | TYK2 | P29597 | 4/20 | 0.48 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099172 | 0.97 | PDE4B (0.52) | PDE4BJAK1JAK2TYK2JAK3 | |
| SCHEMBL14697191 | 0.91 | JAK1 (0.51) | PDE4BJAK1JAK2TYK2JAK3 | |
| SCHEMBL14708561 | 0.90 | JAK3 (0.57) | PDE4BJAK1JAK2TYK2JAK3 | |
| SCHEMBL1933112 | 0.87 | PDE4B (0.58) | PDE4BJAK1JAK3ADORA1ADORA2A | |
| SCHEMBL10099181 | 0.84 | JAK1 (0.42) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL10099187 | 0.84 | JAK1 (0.42) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL20955984 | 0.84 | JAK1 (0.44) | PDE4BJAK1JAK2TYK2JAK3 | |
| SCHEMBL16477564 | 0.84 | NSD2 (0.47) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL14697195 | 0.83 | SCN9A (0.42) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL10099180 | 0.82 | JAK2 (0.45) | JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | PDE4B 2241/4885JAK1 2/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.